Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: BIOLOGICAL: Anti-HER2/HER3 Dendritic Cell Vaccine|BIOLOGICAL: Pembrolizumab
Sponsor: Roswell Park Cancer Institute
Collaborators: United States Department of Defense